why choose us

First received: March 13, 2024

Clinical Trial: Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Schizophrenia, Schizoaffective Disorder

Study Type: INTERVENTIONAL


Official Title: A Multi-center, Open-label, Randomized, Parallel-group Trial to Characterize the Pharmacokinetics of Three SC Olanzapine Extended-Release Formulations With Different Release Rates Following Single Adm

Brief Summary: The primary objective of the study is to characterize the pharmacokinetics of 3 formulations of olanzapine.A secondary objective is to evaluate the safety and tolerability of 3 formulations of olanzapine.Another secondary objective is to characterize the pharmacokinetics of ZYPREXA.The planned duration of the study for each participant is 19 weeks.

Read more